Metformin promotes anticancer activity of NK cells in a p38 MAPK dependent manner

References

• Hodgins JJ, Khan ST, Park MM, Auer RC, Killers AM. 2.0: NK cell therapies at the forefront of cancer control. J Clin Invest. 2019;129(9):3499–14. doi:10.1172/JCI129338.
   PubMed Web of Science ®Google Scholar
• Shimasaki N, Jain A, Campana D. NK cells for cancer immunotherapy. Nat Rev Drug Discov. 2020;19(3):200–218. doi:10.1038/s41573-019-0052-1.
   PubMed Web of Science ®Google Scholar
• Souza-Fonseca-Guimaraes F, Cursons J, Huntington ND. The emergence of natural killer cells as a major target in cancer immunotherapy. Trends Immunol. 2019;40(2):142–158. doi:10.1016/j.it.2018.12.003.
   PubMed Web of Science ®Google Scholar
• Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet. 2000;356(9244):1795–1799. doi:10.1016/S0140-6736(00)03231-1.
   PubMed Web of Science ®Google Scholar
• Lee H, Da Silva IP, Palendira U, Scolyer RA, Long GV, Wilmott JS. Targeting NK Cells to Enhance Melanoma Response to Immunotherapies. Cancers (Basel). 2021;13(6):1363. doi:10.3390/cancers13061363.
   PubMed Web of Science ®Google Scholar
• Pierson BA, Miller JS. CD56+bright and CD56+dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis. Blood. 1996;88(6):2279–2287. doi:10.1182/blood.V88.6.2279.bloodjournal8862279.
   PubMed Web of Science ®Google Scholar
• Cichocki F, Grzywacz B, Miller JS. Human NK cell development: one road or many? Front Immunol. 2019;10:2078. doi:10.3389/fimmu.2019.02078.
   PubMed Web of Science ®Google Scholar
• Myers JA, Miller JS. Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol. 2021;18(2):85–100. doi:10.1038/s41571-020-0426-7.
   PubMed Web of Science ®Google Scholar
• Carotta S. Targeting NK cells for anticancer immunotherapy: clinical and preclinical approaches. Front Immunol. 2016;7:152. doi:10.3389/fimmu.2016.00152.
   PubMed Web of Science ®Google Scholar
• Morvan MG, Lanier LL. NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer. 2016;16(1):7–19. doi:10.1038/nrc.2015.5.
   PubMed Web of Science ®Google Scholar
• Talmadge JE, Meyers KM, Prieur DJ, Starkey JR. Role of NK cells in tumour growth and metastasis in beige mice. Nature. 1980;284(5757):622–624. doi:10.1038/284622a0.
   PubMed Web of Science ®Google Scholar
• Hanna N, Burton RC. Definitive evidence that natural killer (NK) cells inhibit experimental tumor metastases in vivo. J Immunol. 1981;127:1754–1758.
   PubMed Web of Science ®Google Scholar
• Coca S, Perez-Piqueras J, Martinez D, Colmenarejo A, Saez MA, Vallejo C, Martos JA, Moreno M. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer. 1997;79(12):2320–2328. doi:10.1002/(SICI)1097-0142(19970615)79:12<2320::AID-CNCR5>3.0.CO;2-P.
   PubMed Web of Science ®Google Scholar
• Takeuchi H, Maehara Y, Tokunaga E, Koga T, Kakeji Y, Sugimachi K. Prognostic significance of natural killer cell activity in patients with gastric carcinoma: a multivariate analysis. Am J Gastroenterol. 2001;96(2):574–578. doi:10.1111/j.1572-0241.2001.03535.x.
   PubMed Web of Science ®Google Scholar
• Suen WC, Lee WY, Leung KT, Pan XH, Li G. Natural killer cell-based cancer immunotherapy: a review on 10 years completed clinical trials. Cancer Invest. 2018;36(8):431–457. doi:10.1080/07357907.2018.1515315.
   PubMed Web of Science ®Google Scholar
• Grossenbacher SK, Aguilar EG, Murphy WJ. Leveraging natural killer cells for cancer immunotherapy. Immunotherapy. 2017;9(6):487–497. doi:10.2217/imt-2017-0013.
   PubMed Web of Science ®Google Scholar
• Guillerey C, Huntington ND, Smyth MJ. Targeting natural killer cells in cancer immunotherapy. Nat Immunol. 2016;17(9):1025–1036. doi:10.1038/ni.3518.
   PubMed Web of Science ®Google Scholar
• Brehm C, Huenecke S, Esser R, Kloess S, Quaiser A, Betz S, Zimmermann O, Soerensen J, Passweg JR, Klingebiel T, et al. Interleukin-2-stimulated natural killer cells are less susceptible to mycophenolate mofetil than non-activated NK cells: possible consequences for immunotherapy. Cancer Immunol Immunother. 2014;63(8):821–833. doi:10.1007/s00262-014-1556-5.
   PubMed Web of Science ®Google Scholar
• Conlon KC, Lugli E, Welles HC, Rosenberg SA, Fojo AT, Morris JC, Fleisher TA, Dubois SP, Perera LP, Stewart DM, et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J Clin Oncol. 2015;33(1):74–82. doi:10.1200/JCO.2014.57.3329.
   PubMed Web of Science ®Google Scholar
• Morales DR, Morris AD. Metformin in cancer treatment and prevention. Annu Rev Med. 2015;66(1):17–29. doi:10.1146/annurev-med-062613-093128.
   PubMed Web of Science ®Google Scholar
• Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005;330(7503):1304–1305. doi:10.1136/bmj.38415.708634.F7.
   PubMed Web of Science ®Google Scholar
• Quinn BJ, Kitagawa H, Memmott RM, Gills JJ, Dennis PA. Repositioning metformin for cancer prevention and treatment. Trends Endocrinol Metab. 2013;24(9):469–480. doi:10.1016/j.tem.2013.05.004.
   PubMed Web of Science ®Google Scholar
• Curry JM, Johnson J, Mollaee M, Tassone P, Amin D, Knops A, Whitaker-Menezes D, Mahoney MG, South A, Rodeck U, et al. Metformin Clinical Trial in HPV+ and HPV− Head and Neck Squamous Cell Carcinoma: impact on Cancer Cell Apoptosis and Immune Infiltrate. Front Oncol. 2018;8:436. doi:10.3389/fonc.2018.00436.
   PubMed Web of Science ®Google Scholar
• Petrera M, Paleari L, Clavarezza M, Puntoni M, Caviglia S, Briata IM, Oppezzi M, Mislej EM, Stabuc B, Gnant M, et al. The ASAMET trial: a randomized, phase II, double-blind, placebo-controlled, multicenter, 2x2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients. BMC Cancer. 2018;18(1):1210. doi:10.1186/s12885-018-5126-7.
   PubMed Web of Science ®Google Scholar
• Higurashi T, Hosono K, Takahashi H, Komiya Y, Umezawa S, Sakai E, Uchiyama T, Taniguchi L, Hata Y, Uchiyama S, et al. Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial. Lancet Oncol. 2016;17(4):475–483. doi:10.1016/S1470-2045(15)00565-3.
   PubMed Web of Science ®Google Scholar
• Martin-Castillo B, Pernas S, Dorca J, Alvarez I, Martinez S, Perez-Garcia JM, Batista-López N, Rodríguez-Sánchez CA, Amillano K, Domínguez S, et al. A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study. Oncotarget. 2018;9(86):35687–35704. doi:10.18632/oncotarget.26286.
   PubMedGoogle Scholar
• Eikawa S, Nishida M, Mizukami S, Yamazaki C, Nakayama E, Udono H. Immune-mediated antitumor effect by type 2 diabetes drug, metformin. Proc Natl Acad Sci U S A. 2015;112:1809–1814.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Li F, Tian Y, Cao L, Gao Q, Zhang C, Zhang K, Shen C, Ping Y, Maimela NR, et al. Metformin Enhances the Antitumor Activity of CD8+T Lymphocytes via the AMPK–miR-107–Eomes–PD-1 Pathway. J Immunol. 2020;204(9):2575–2588. doi:10.4049/jimmunol.1901213.
   PubMed Web of Science ®Google Scholar
• Cha JH, Yang WH, Xia W, Wei Y, Chan LC, Lim SO, Li C-W, Kim T, Chang -S-S, Lee -H-H, et al. Metformin promotes antitumor immunity via endoplasmic-reticulum-associated degradation of PD-L1. Mol Cell. 2018;71(4):606–620. doi:10.1016/j.molcel.2018.07.030.
   PubMed Web of Science ®Google Scholar
• Uehara T, Eikawa S, Nishida M, Kunisada Y, Yoshida A, Fujiwara T, Kunisada T, Ozaki T, Udono H. Metformin induces CD11b+-cell-mediated growth inhibition of an osteosarcoma: implications for metabolic reprogramming of myeloid cells and anti-tumor effects. Int Immunol. 2019;31(4):187–198. doi:10.1093/intimm/dxy079.
   PubMed Web of Science ®Google Scholar
• Li L, Wang L, Li J, Fan Z, Yang L, Zhang Z, Zhang C, Yue D, Qin G, Zhang T, et al. Metformin-induced reduction of CD39 and CD73 blocks myeloid-derived suppressor cell activity in patients with ovarian cancer. Cancer Res. 2018;78(7):1779–1791. doi:10.1158/0008-5472.CAN-17-2460.
   PubMed Web of Science ®Google Scholar
• Kim K, Yang W-H, Jung Y-S, Cha J-H. A new aspect of an old friend: the beneficial effect of metformin on anti-tumor immunity. BMB Rep. 2020;53(10):512–520. doi:10.5483/BMBRep.2020.53.10.149.
   PubMed Web of Science ®Google Scholar
• Zhen L, Jiacheng B, Wan X. Artemisinin sensitizes tumor cells to NK cell-mediated cytolysis. Biochem Biophys Res Commun. 2020;524(2):418–423. doi:10.1016/j.bbrc.2020.01.094.
   PubMed Web of Science ®Google Scholar
• Smyth MJ, Hayakawa Y, Takeda K, Yagita H. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer. 2002;2(11):850–861. doi:10.1038/nrc928.
   PubMed Web of Science ®Google Scholar
• Gotthardt D, Trifinopoulos J, Sexl V, Putz EM. JAK/STAT Cytokine Signaling at the Crossroad of NK Cell Development and Maturation. Front Immunol. 2019;10:2590. doi:10.3389/fimmu.2019.02590.
   PubMed Web of Science ®Google Scholar
• Ali AK, Nandagopal N, Lee SH. IL-15-PI3K-AKT-mTOR: a critical pathway in the life journey of natural killer cells. Front Immunol. 2015;6:355. doi:10.3389/fimmu.2015.00355.
   PubMed Web of Science ®Google Scholar
• Ruixia M, Bin Y, Riker AI, Yaguang X. Metformin and cancer immunity. Acta Pharmacol Sin. 2020;41(11):1403–1409. doi:10.1038/s41401-020-00508-0.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Liu F, Sanhua L, Jiang N, Changyan Y, Zhu X, Qin Y, Hui J, Liangjie M, Changwei S, et al. Metformin promotes innate immunity through a conserved PMK-1/p38 MAPK pathway. Virulence. 2019. doi:10.1080/21505594.2019.1706305.
   Web of Science ®Google Scholar
• Karre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature. 1986;319(6055):675–678. doi:10.1038/319675a0.
   PubMed Web of Science ®Google Scholar
• Gascoyne DM, Long E, Veiga-Fernandes H, De Boer J, Williams O, Seddon B, Coles M, Kioussis D, Brady HJM. The basic leucine zipper transcription factor E4BP4 is essential for natural killer cell development. Nat Immunol. 2009;10(10):1118–1124. doi:10.1038/ni.1787.
   PubMed Web of Science ®Google Scholar
• Merzoug LB, Marie S, Satoh-Takayama N, Lesjean S, Albanesi M, Luche H, Fehling HJ, Santo JPD, Vosshenrich CAJ. Conditional ablation of NKp46+cells using a novel Ncr1greenCre mouse strain: NK cells are essential for protection against pulmonary B16 metastases. Eur J Immunol. 2014;44(11):3380–3391. doi:10.1002/eji.201444643.
   PubMed Web of Science ®Google Scholar
• Ochayon DE, Ali A, Alarcon PC, Krishnamurthy D, Kottyan LC, Borchers MT. IL-33 promotes type 1 cytokine expression via p38 MAPK in human NK cells. J Leukoc Biol. 2020;107(4):663-671.
   PubMed Web of Science ®Google Scholar
• Sciannimanico S, Grimaldi F, Vescini F, De Pergola G, Iacoviello M, Licchelli B, Guastamacchia E, Giagulli VA, Triggiani V. Metformin: up to Date. Endocr Metab Immune Disord Drug Targets. 2020;20(2):172–181. doi:10.2174/1871530319666190507125847.
   PubMed Web of Science ®Google Scholar
• Pesce S, Greppi M, Tabellini G, Rampinelli F, Parolini S, Olive D, Moretta L, Morreta A, Marcenaro E. Identification of a subset of human NK cells expressing high levels of PD-1 receptor: a phenotypic and functional characterization. J Allergy Clin Immunol. 2017;139(1):335–346. doi:10.1016/j.jaci.2016.04.025.
   PubMed Web of Science ®Google Scholar
• Benson DM, Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, Baiocchi RA, Zhang J, Yu J, Smith MK. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti– PD-1 antibody. Blood. 2010;116(13):2286–2294. doi:10.1182/blood-2010-02-271874.
   PubMed Web of Science ®Google Scholar
• Wang SH, Lin YS, Xiong X, Wang L, Guo Y, Chen YP. Low-dose metformin reprograms the tumor immune microenvironment in human esophageal cancer: results of a phase II clinical trial. Clin Cancer Res. 2020;26(18):4921–4932. doi:10.1158/1078-0432.CCR-20-0113.
   PubMed Web of Science ®Google Scholar
• Srivastava RM, Lee SC, Pedro A, Filho A, Lord CA, Jie H-B, Davidson HC, Gibson SP, Gooding WE, Ferrone S, et al. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res. 2013;19(7):1858–1872. doi:10.1158/1078-0432.CCR-12-2426.
   PubMed Web of Science ®Google Scholar
• Bald T, Krummel MF, Smyth MJ, Barry KC. The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies. Nat Immunol. 2020;21(8):835–847. doi:10.1038/s41590-020-0728-z.
   PubMed Web of Science ®Google Scholar